Sources and Guidelines Referenced

Clinical information in this guide is grounded in international consensus guidelines and peer-reviewed evidence from the following bodies and landmark studies: International Society of Ultrasound in Obstetrics and Gynecology (ISUOG Practice Guidelines, 2023 update on mid-trimester fetal ultrasound); American College of Obstetricians and Gynecologists (ACOG Practice Bulletin No. 229, 2021); American Institute of Ultrasound in Medicine (AIUM Practice Parameter for Obstetric Ultrasound, 2023); Royal College of Obstetricians and Gynaecologists (RCOG Fetal Anomaly Screening Standards, 2022); Society for Maternal-Fetal Medicine (SMFM Consult Series, 2021); and Salomon et al., Ultrasound in Obstetrics & Gynecology (2019).

Anomaly Scan (Level II Ultrasound): A Comprehensive Patient Guide

1. Definition and Medical Identity

An anomaly scan is a detailed non-invasive diagnostic ultrasound performed between 18 and 22 weeks of pregnancy to evaluate fetal anatomy, growth, placental position, and amniotic fluid. Also known as a Level II ultrasound, anatomical survey, or target scan, this obstetrical imaging procedure systematic evaluates structural development across all fetal organ systems.

In contrast to a standard basic (Level I) screening scan, which primarily checks fetal heart rate, gross growth parameters, and pregnancy viability, a Level II anomaly scan follows rigid standardized protocols set by global guidelines such as ISUOG and ACOG. The targeted examination systematically views specific biological cross-sections of the fetal cranium, heart, spine, kidneys, gastrointestinal tract, facial structures, and skeleton. Its overarching diagnostic goal is to confirm normal structural development, detect congenital anomalies, refine chromosomal risk profiles, and establish an early clinical foundation for specialized prenatal or neonatal management.

2. The Underlying Condition or Need

An anomaly scan is a standard prenatal screening tool recommended for all pregnant individuals to evaluate structural development and detect congenital anomalies. Structural birth defects occur in approximately 2% to 3% of all live births worldwide (World Health Organization, 2023). These structural variations can affect any organ system and range from minor, treatable anatomical defects to severe, life-limiting conditions.

Many fetuses with structural birth defects develop in pregnancies with zero known risk factors, high-risk family history, or abnormal first-trimester screens. Without systematic imaging, complex internal malformations—such as congenital heart defects, spina bifida, diaphragmatic hernia, or renal agenesis—may go unrecognized until delivery, leading to unpredictable emergency interventions. The natural trajectory of unmonitored structural conditions can lead to adverse maternal-fetal outcomes, unexpected intrapartum complications, or delayed neonatal resuscitation. A Level II ultrasound provides clear visualization, enabling timely interventions, specialized counseling, maternal transfer to tertiary surgical centers, or in-utero fetal therapy when indicated.

3. How the Treatment Works — Mechanism

An anomaly scan relies on the physics of high-frequency acoustic sound waves to generate real-time cross-sectional imagery of pelvic and fetal structures without using ionizing radiation. Acoustic transducers emit high-frequency sound waves (typically 3.5 to 5.0 Megahertz) into maternal abdominal tissues, which pass through the abdomen, uterine wall, and amniotic fluid.

As these acoustic waves encounter boundary interfaces between different biological tissues—such as fluid, muscle, organ parenchytra, and ossifying fetal bone—portions of the sound waves are reflected back to the transducer. Bone reflects a high percentage of sound, appearing bright white (echogenic) on screen, while fluid transmits sound completely, appearing dark black (anechoic). Tissue densities fall within greyscale gradients. Modern ultrasound machines measure the time delay and intensity of reflected echoes to generate high-resolution, real-time 2D and 3D anatomical images. By manipulating the transducer across precise acoustic planes, clinicians examine internal anatomical structures, measure spatial distances down to fractions of a millimeter, and apply Doppler ultrasound to assess blood flow dynamics through the umbilical cord, fetal heart chambers, and cerebral blood vessels.

4. Types and Variations

The anomaly scan is customized based on patient clinical presentation, maternal body habitus, fetal position, and specific diagnostic findings. While the standard 2D transabdominal scan remains the clinical baseline, complementary techniques are integrated into the protocol as required by guidelines (AIUM, 2023).

Ultrasound Variation	Primary Clinical Indication	Key Technical Features	Clinical Advantages
Transabdominal 2D Ultrasound	Routine mid-trimester screening (18–22 weeks) for all pregnant patients.	Standard curved-array abdominal probe (3.5–5 MHz). Cross-sectional grayscale images.	Broad acoustic field, comprehensive systemic anatomical evaluation, completely non-invasive.
Transvaginal Ultrasound (TVUS)	Incomplete pelvic visualization, high maternal BMI, low-lying placenta evaluation, or cervical length screening.	High-frequency internal probe (5–9 MHz) placed in the vaginal canal near the cervix.	Superior spatial resolution, precise measurement of cervical length, clear imaging of pelvic structures.
Targeted Fetal Echocardiography	Suspected cardiac anomaly, elevated nuchal translucency, pregestational diabetes, or family history of CHD.	High-frame-rate specialized ultrasound probes with color and pulse-wave Doppler analysis.	Detailed multiplane examination of fetal heart architecture, valve function, and outflow tracts.
3D / 4D Ultrasound	Clarification of superficial facial anomalies (e.g., cleft lip), limb dysplasias, or spinal defects.	Volumetric rendering algorithms projecting 3D static or real-time (4D) spatial images.	Enhanced surface tissue visualization, improved patient comprehension, precise volume measurement.

Clinicians select specific imaging variations during the exam depending on diagnostic requirements. If abdominal wall tissue depth limits acoustic penetration, or if the fetal head is engaged deep in the maternal pelvis, a transvaginal approach provides high-frequency visual clarity for intracranial, cervical, or placental assessment (ISUOG Guidelines, 2023).

5. Who the Treatment Is For — Indications

According to clinical consensus guidelines from ACOG (Practice Bulletin No. 229) and ISUOG, a mid-trimester Level II anomaly scan is recommended for all pregnant individuals between 18+0 and 22+6 weeks of gestation as part of routine antenatal care. While universal screening is standard, specific high-risk clinical indications demand enhanced diagnostic detail or early evaluation:

• Maternal Medical Conditions: Pregestational type 1 or type 2 diabetes, autoimmune disorders (e.g., systemic lupus erythematosus), or maternal phenylketonuria.
• Teratogenic Exposures: Maternal exposure to known teratogenic medications (e.g., anti-seizure agents, ACE inhibitors, retinoids), active infections (e.g., cytomegalovirus, toxoplasmosis, Zika virus), or toxic environmental substances.
• Abnormal Screening Results: A high-risk cell-free DNA (cfDNA/NIPS) result, abnormal first-trimester serum biochemistry, or elevated nuchal translucency (>3.5 mm).
• Family or Prior History: Previous child or immediate family history of congenital structural defects, chromosomal anomalies, or genetic syndromes.
• Multiple Gestations: Twin, triplet, or higher-order multifetal pregnancies requiring evaluation of chorionicity, vascular anastomoses, and growth symmetry.
• Obstetric and Physical Markers: Abnormal baseline scan findings, advanced maternal age (≥35 years at delivery), elevated maternal serum alpha-fetoprotein (MSAFP), or oligohydramnios/polyhydramnios.

6. Who the Treatment Is NOT For — Contraindications

Diagnostic prenatal ultrasound has no absolute biological or medical contraindications. Ultrasound uses sound waves rather than ionizing radiation, making it clinically safe for the mother and fetus at any stage of pregnancy when used appropriately (AIUM, 2023).

Relative contraindications or clinical limitations relate primarily to timing and physical factors rather than safety risks:

• Gestational Timing Out of Bounds: Performing the primary anomaly scan prior to 18 weeks is relatively contraindicated because fetal organ structures—particularly the cardiac outflow tracts and cerebral vermis—are insufficient in size for reliable visual confirmation. Performing the initial scan after 24 weeks limits diagnostic accuracy and options for invasive testing or specialized care planning.
• Severe Abdominal Wall Barriers: Open abdominal wounds, active localized cutaneous infections (e.g., severe herpes zoster outbreak across the abdominal skin), or fresh surgical dressings may restrict transducer placement. In these settings, a transvaginal approach or delayed scan is performed.
• Refusal of Diagnostic Testing: An individual retains the right to decline routine screening after informed consent discussions regarding the benefits and limitations of anatomical surveillance.

7. Alternatives and Clinical Comparison

While the Level II anomaly scan is the clinical standard for comprehensive structural evaluation in the mid-trimester, alternative and adjunct modalities provide specific diagnostic information across different stages of pregnancy.

Diagnostic Modality	Optimal Timing	Primary Diagnostic Focus	Invasiveness	Key Clinical Trade-offs
Level II Anomaly Scan	18–22 Weeks	Systemic structural anomaly screening, growth biometry, placenta/fluid assessment.	Non-invasive (Transabdominal)	Standard of care for morphology; limited by fetal position and maternal habitus.
First-Trimester Scan (NT Scan)	11–13+6 Weeks	Aneuploidy risk stratification, gross structural screening, early viability.	Non-invasive (Transabdominal/TVUS)	Identifies major anomalies early; organ systems not fully formed for comprehensive detail.
Cell-Free DNA (cfDNA / NIPS)	10+ Weeks onward	Screening for Trisomies 21, 18, 13, and sex chromosome aneuploidies.	Non-invasive (Maternal Blood Draw)	Extremely high sensitivity for specific trisomies; cannot detect non-chromosomal structural defects.
Fetal Magnetic Resonance Imaging (MRI)	22+ Weeks	Detailed brain morphology, complex lung lesions, diaphragmatic hernia quantification.	Non-invasive (No Ionizing Radiation)	Superior soft-tissue contrast; higher cost, limited accessibility, used primarily as a second-line tool.
Amniocentesis	15–20+ Weeks	Definitive chromosomal microarray, karyotyping, and genetic sequencing.	Invasive (Transabdominal Needle Aspiration)	Provides definitive genetic diagnosis; carries a small procedure-related pregnancy loss risk (~0.1–0.3%).

Clinicians utilize cfDNA or early first-trimester scans as complementary screens rather than direct replacements for the Level II anomaly scan. cfDNA evaluates molecular chromosomal risk but cannot visualize structural organ architecture, such as a cleft palate or ventricular septal defect. Consequently, an anomaly scan remains an irreplaceable component of second-trimester care regardless of normal early blood screening results (ACOG Practice Bulletin No. 229).

8. Pre-Treatment Phase

Preparation for an anomaly scan involves simple steps designed to optimize image resolution and ensure clear anatomical visualization. The pre-procedure process focuses on gathering history, timing the scan correctly, and ensuring patient comfort.

Initial consultation includes a comprehensive review of maternal medical history, prior obstetric outcomes, family history of congenital disorders, and results from earlier screening tests (such as first-trimester biochemistry or cell-free DNA). The optimal clinical window is strictly between 18+0 and 22+6 weeks of gestation. At this developmental stage, the balance between fetal size, amniotic fluid volume, and bone ossification provides optimal acoustic windows for anatomical inspection.

Patients are advised to wear comfortable, two-piece clothing to facilitate exposure of the lower abdomen. A moderately full urinary bladder is often requested if the scan is performed at 18 weeks, as it helps lift the uterus out of the pelvic cavity; however, for scans closer to 20–22 weeks, amniotic fluid typically provides adequate visual contrast without requiring excessive bladder filling. Fasting is unnecessary. In fact, consuming a light meal or fruit juice 20 to 30 minutes prior to the examination can increase fetal movement, helping the fetus move out of persistent, difficult positions that shield key structures from view (Salomon et al., 2019).

9. The Procedure — Step-by-Step Clinical Detail

The Level II anomaly scan is a systematic examination conducted in an outpatient imaging suite or maternal-fetal medicine clinic. The complete examination typically takes 30 to 45 minutes, though fetal position or maternal tissue density may extend this duration.

Step 1: Patient Positioning and Acoustic Medium Application

The patient is positioned comfortably in a semi-recumbent position on an examination table, with a slight lateral tilt to minimize compression of the inferior vena cava and prevent maternal hypotension. Warm, water-based acoustic gel is applied across the lower abdomen to eliminate air pockets between the skin and the ultrasound transducer, ensuring clear sound wave transmission.

Step 2: Fetal Orientation, Number, and Viability

The operator begins by placing the transducer on the maternal abdomen to confirm fetal heart activity and determine fetal number and presentation (cephalic, breech, or transverse). Fetal cardiac rate and rhythm are calculated using M-mode or Doppler ultrasound.

Step 3: Biometric Evaluation

The clinician takes targeted spatial measurements to verify gestational age and monitor fetal growth:

• Biparietal Diameter (BPD) & Head Circumference (HC): Measured at the axial plane showing the thalami and septum pellucidum.
• Abdominal Circumference (AC): Measured at the transverse plane displaying the junction of the portal vein and the stomach bubble.
• Femur Length (FL): Measured along the main shaft (diaphysis) of the femur, excluding epiphyses.

Step 4: Systemic Anatomical Survey

Following ISUOG 2023 guidelines, the operator conducts a thorough organ-by-organ anatomical evaluation:

• Central Nervous System: Inspection of intact cranial bones, lateral ventricles (measuring atrial width <10 mm), midline falx, thalami, cerebellum, and cisterna magna.
• Facial Profile: Verification of both orbits, nose/nostrils, upper lip integrity to exclude clefts, and side profile (mandible/maxilla).
• Thorax and Heart: Evaluation of lung fields, diaphragmatic integrity, four distinct cardiac chambers, left and right ventricular outflow tracts, and the three-vessel trachea (3VT) view.
• Abdomen and Gastrointestinal: Confirmation of stomach bubble position on the left, intestinal echogenicity, liver structures, and continuous anterior abdominal wall at the umbilical cord insertion site.
• Genitourinary System: Visualization of both kidneys in renal fossae (checking for hydronephrosis/pyelectasis), clear renal arteries via color Doppler, and a filled urinary bladder.
• Spine and Skeleton: Longitudinal and axial cross-sectional sweeps through the cervical, thoracic, lumbar, and sacral spine, checking skin coverage; confirmation of three long bones in each arm and leg, and alignment of hands and feet.

Step 5: Placenta, Amniotic Fluid, and Cervix

The operator documents placental location relative to the internal os of the cervix, evaluates placental structure, counts three vessels in the umbilical cord (two arteries, one vein), measures amniotic fluid levels (single deepest pocket or amniotic fluid index), and evaluates cervical length transabdominally or transvaginally if clinically indicated.

10. Immediate Post-Procedure Period

Once the scan is complete, excess gel is wiped from the patient's abdomen, and the patient can immediately sit up and resume light activity. There are no restrictions, recovery room observations, or activity limitations following a non-invasive diagnostic ultrasound.

If the scan was performed by a specialized sonographer, a maternal-fetal medicine consultant or radiologist reviews the saved digital images and cine clips. In many clinical settings, a immediate verbal debriefing is provided to the patient to discuss preliminary findings. A formal, written clinical report detailing biometry, organ visualization, placental site, and fluid levels is compiled and placed in the patient’s medical records, with a copy routed to the primary managing obstetrician or midwife. If any structural abnormality or soft marker is identified, the clinician discusses the findings directly with the patient in a quiet counseling room on the same day.

11. Recovery — Short and Long Term

Because an anomaly scan involves no surgical incisions, systemic medications, or ionizing radiation, physical recovery is immediate. Patients require no downtime and can return to work, drive, exercise, and engage in daily activities right after their appointment.

If a transvaginal ultrasound was required during the session to assess cervical length or low placental positioning, mild transient pressure or localized discomfort may occur, which resolves within minutes. If gel remains on the skin, it is water-soluble and easily washes off without skin irritation.

From a psychological perspective, if an anomaly or soft marker is identified, the long-term clinical trajectory shifts toward diagnostic confirmation and multidisciplinary management. This pathway may involve scheduling targeted fetal echocardiography within 1 to 2 weeks, arranging a genetic consultation, or planning repeat ultrasound evaluations every 2 to 4 weeks to monitor fetal growth and fluid balance throughout the third trimester.

12. Risks, Side Effects, and Complications

Diagnostic ultrasound is a safe diagnostic tool with no known biological risks to the mother or developing fetus when performed within standard clinical guidelines (AIUM, 2023). Unlike X-rays or CT scans, ultrasound does not use ionizing radiation.

Risk Category	Clinical Description	Incidence / Frequency	Management Strategy
Physical / Biological Harm	Tissue heating or acoustic cavitation from ultrasound energy output.	Zero recorded cases under diagnostic clinical standards.	Monitoring of Thermal Index (TI < 1.0) and Mechanical Index (MI < 1.0) per ALARA principle.
Maternal Supine Hypotension	Dizziness or nausea caused by uterine compression of the inferior vena cava while lying flat.	Uncommon (~5–10% of mid-trimester patients).	Immediate repositioning of the patient to a left lateral tilt; elevating head of bed.
Psychological Distress	Anxiety arising from complex, ambiguous, or unexpected structural findings.	Varies; elevated during identification of soft markers.	Direct physician debriefing, dedicated genetic counseling, prompt diagnostic clarification.
Diagnostic Limitations	Inability to visualize all structures due to fetal position, maternal habitus, or oligohydramnios.	Occurs in 10–15% of initial scans.	Scheduling a repeat scan in 1–2 weeks; utilizing transvaginal probes or fetal MRI.

To preserve biological safety, equipment operators adhere strictly to the ALARA principle—As Low As Reasonably Achievable—adjusting power output and keeping exposure times focused. The Thermal Index (TI) for soft tissue or bone and the Mechanical Index (MI) are continuously monitored on-screen to ensure they remain well below safety thresholds (TI < 1.0, MI < 1.0). The primary diagnostic challenge involves false positives (identifying a potential variance that resolves or proves non-significant) or false negatives (structural anomalies missed due to acoustic barriers or early developmental stage).

13. Lifestyle and Behavioural Considerations

Lifestyle modifications around the time of an anomaly scan center on maternal health and optimizing diagnostic imaging conditions. There are no strict post-scan behavioral or physical restrictions.

To support clear visualization, patients should maintain standard daily hydration leading up to the procedure, as proper maternal hydration promotes adequate amniotic fluid volume. Taking recommended prenatal vitamins, including folic acid, remains important throughout early and mid-pregnancy for structural organ maintenance. On the day of the scan, patients do not need to restrict activity or change their diet. If a patient experiences significant anxiety regarding potential scan results, practicing mindfulness techniques or bringing a partner or support person to the examination can provide emotional support.

14. How Outcomes Are Measured

The success of an anomaly scan is measured by diagnostic completeness, acoustic visual quality, and accurate risk stratification rather than a direct treatment outcome.

Clinicians grade ultrasound quality based on the systematic visualization of required anatomical planes mandated by ISUOG and ACOG guidelines. Complete visualization means that all organ systems, biometric measurements, placental boundaries, and amniotic fluid compartments have been clearly evaluated and documented. Diagnostic sensitivity for major structural malformations ranges between 70% and 85%, depending on the specific organ system examined (Salomon et al., 2019):

• Central Nervous System Defects: Detection rates exceed 90–95% for major open neural tube defects like anencephaly and spina bifida.
• Renal Anomalies: Detection rates range from 80% to 90% for severe bilateral renal disorders or significant hydronephrosis.
• Congenital Heart Defects (CHDs): Basic four-chamber evaluation identifies approximately 50–60% of major CHDs; incorporating outflow tract and 3VT views increases detection rates to 80–85% (ISUOG Guidelines, 2023).
• Abdominal Wall Defects: Detection rates exceed 90% for gastroschisis and omphalocele.

If an initial scan is incomplete due to suboptimal fetal position, elevated maternal body mass index (BMI), or uterine fibroids, the standard protocol calls for a repeat ultrasound in 1 to 2 weeks. If complex structural anomalies are identified, success is defined as establishing an accurate diagnosis, facilitating early genetic evaluation, and seamlessly coordinating care with pediatric surgeons and neonatologists prior to delivery.

15. Recent Advances and Current Standard of Care

Obstetric imaging has advanced significantly over the past decade. Standard 2D ultrasound machines now feature higher transducer crystal densities, advanced digital noise reduction, and speckle-reduction imaging algorithms, providing exceptional spatial resolution of delicate fetal structures.

The current clinical standard of care requires multiplane cardiac outflow tract evaluation (including the four-chamber view, left and right ventricular outflow tracts, and the three-vessel trachea view) as part of standard routine screening (ISUOG, 2023). Modern high-end ultrasound systems integrate high-definition directional Doppler to evaluate small microvascular structures, such as fetal renal arteries and intracranial vessels. Automated 3D/4D volumetric software now allows clinicians to reconstruct complex anatomical planes, such as the secondary fetal palate and spinal arches, rendering detailed spatial models that assist in surgical planning and diagnostic clarification. Furthermore, artificial intelligence algorithms are emerging in modern platforms to automatically verify standard biometric planes and suggest structural measurements, reducing operator variability and improving diagnostic efficiency.

16. Common Myths and Misconceptions

Myth: An anomaly scan can detect every single birth defect or developmental disorder.
Reality: While an anomaly scan detects 70–85% of major structural defects, it cannot identify microscopic genetic defects, neurodevelopmental delays, autism, or subtle structural issues that manifest late in the third trimester or after birth (ACOG Practice Bulletin No. 229).

Myth: Frequent ultrasound sound waves emit harmless levels of radiation to the baby.
Reality: Ultrasound technology relies entirely on high-frequency sound waves (acoustic energy) and uses zero ionizing radiation. Decades of clinical study demonstrate its physical safety when performed under standard guidelines.

Myth: Having a normal cell-free DNA (cfDNA) blood test means a patient can safely skip the Level II anomaly scan.
Reality: Cell-free DNA screens for specific chromosomal numerical variations (such as Trisomy 21), but it cannot detect physical structural defects like heart malformations, spina bifida, or cleft lip. The anomaly scan remains essential for all patients regardless of cfDNA results.

Myth: A full, painful bladder is required for a 20-week anomaly scan.
Reality: At 18 to 22 weeks, the uterus has expanded into the abdomen and is surrounded by amniotic fluid, providing a clear acoustic window. Excessive bladder filling is unnecessary and can cause discomfort or distort cervical length measurements.

Myth: If the sonographer is quiet during the scan, it means something is medically wrong with the baby.
Reality: Conducting a Level II anomaly scan requires intense concentration to evaluate minute anatomical structures and take exact millimeter-level measurements. A quiet practitioner is simply focusing on completing the complex diagnostic checklist accurately.

Myth: Soft markers found on an anomaly scan mean the baby definitely has a severe birth defect.
Reality: Soft markers (such as choroid plexus cysts or echogenic intracardiac foci) are often temporary anatomical variations found in healthy fetuses. They slightly adjust calculated background risk but usually resolve on their own without causing physical or intellectual harm.

17. Frequently Asked Questions

What is the best week to get an anomaly scan done?

The optimal timing for a Level II anomaly scan is between 18+0 and 22+6 weeks of gestation. During this period, fetal organs are well-developed and large enough for detailed visualization, and amniotic fluid volume provides excellent acoustic contrast for anatomical evaluation.

How does a Level II ultrasound differ from a standard Level I ultrasound?

A Level I scan checks basic parameters like fetal heart rate, gross movement, fluid levels, and basic growth measurements. A Level II anomaly scan is a detailed diagnostic survey evaluating precise organ architecture, intracranial brain structures, cardiac outflow tracts, facial structures, renal anatomy, spinal continuity, and placental attachment.

Can an anomaly scan accurately determine the baby's sex?

Yes, external genitalia are usually clearly visualizable during the 18 to 22-week scan, assuming the fetus is in a favorable position. However, determining sex is secondary to the primary clinical objective of systematic anatomical evaluation.

What happens if the fetal position prevents the sonographer from seeing everything?

If the fetus is facing backward or tucked deep in the pelvis, the sonographer may ask you to turn sideways, take a short walk, or drink water to encourage movement. If key anatomical structures remain hidden, a follow-up scan is scheduled 1 to 2 weeks later.

Is an anomaly scan safe for my developing baby?

Yes, diagnostic prenatal ultrasound has been clinically used for over 50 years with an exceptional safety record. It utilizes non-ionizing acoustic sound waves rather than radiation and adheres strictly to output indices (TI and MI below 1.0) according to the ALARA biological safety principle.

How accurate is an anomaly scan for detecting heart defects?

Standard four-chamber cardiac views detect approximately 50-60% of major congenital heart defects. When expanded to include left/right outflow tracts and three-vessel views according to ISUOG guidelines, detection rates reach 80-85% for structural cardiac malformations.

What is a soft marker on an ultrasound?

A soft marker is a minor anatomical variation—such as a choroid plexus cyst, echogenic intracardiac focus, or slightly dilated renal pelvis—that is often seen in healthy fetuses, but can modestly alter the baseline risk profile for underlying chromosomal variations.

Will I get the results of my anomaly scan immediately?

In many clinics, preliminary findings are discussed right after the scan. However, a maternal-fetal specialist or radiologist must formally review all archived images and biometry to issue a final written diagnostic report to your managing obstetrician.

Can an anomaly scan detect autism or intellectual disabilities?

No, an anomaly scan evaluates structural organ anatomy and physical development. It cannot assess brain function, intellectual potential, learning difficulties, or neurobehavioral conditions such as autism spectrum disorder.

Why might a transvaginal scan be needed during an anomaly scan?

A transvaginal ultrasound may be added if the fetal head is low in the pelvis, maternal body habitus restricts transabdominal ultrasound penetration, or clinicians need to precisely measure cervical length and evaluate a low-lying placenta near the internal os.

Do I need an anomaly scan if my first-trimester screening was completely normal?

Yes. First-trimester screens calculate statistical risks for specific chromosomal syndromes but cannot evaluate structural organ architecture. Many severe physical defects occur independently of chromosomal anomalies and can only be detected during a mid-trimester structural scan.

What steps follow if a structural anomaly is identified on the scan?

If an anomaly is detected, you will be offered a detailed consultation with a maternal-fetal medicine specialist. Follow-up options may include targeted fetal echocardiography, genetic counseling, amniocentesis, fetal MRI, or coordinated care planning with pediatric specialists.

Can maternal body weight affect the visual clarity of the scan?

Increased abdominal adipose tissue scatters ultrasound waves, which can reduce acoustic penetration and image clarity. Clinicians adjust frequency settings, utilize harmonic imaging, or incorporate transvaginal approaches to obtain necessary diagnostic detail.

or transvaginal approaches to obtain necessary diagnostic detail.